Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.

Mr. Emili Torrell Cortada

Chief Business Development Officer

Dr. Douglas V. Faller M.D., Ph.D.

Global Chief Medical Officer

Dr. Carlos Manuel Buesa Arjol

Co-Founder, Chairman, Chief Executive Officer & President

Dr. Ana  Limon

Senior Vice President of Clinical Development & Global Medical Affairs

Mr. Enric Rello Condomines

Director of Operations, Chief Operating Officer & Chief Financial Officer

Mr. Jordi Xaus Pey

Chief Scientific Officer

Mr. Xavier Perpinya Ribera

Head of Internal Audit & Compliance

Ms. Neus Virgili Bernado

Chief Intellectual Property Officer

Dr. Michael Thomas Ropacki Ph.D.

Chief Medical Officer of CNS

Ms. Sonia Paloma Gutierrez Bezon

Chief of Clinical Operations

Oryzon Genomics S.A.

Oryzon Genomics S.A. Vadības struktūra

Informācija par vadību